Atara bio tab-cel
WebSep 27, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel ® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD ... WebTab-cel ®, Atara's most clinically advanced T-cell immunotherapy in development, is currently being investigated in the Phase 3 registration-enabling ALLELE study to assess efficacy and safety for the treatment of …
Atara bio tab-cel
Did you know?
WebNov 30, 2024 · Atara will present findings from the ALLELE study and additional tab-cel data in eight abstracts at the 63 rd American Society of Hematology (ASH) Annual Meeting taking place December 11-14, 2024 ... WebJan 9, 2024 · tab-cel® ATA129; EBV-CTL; Outcome Measures ... Atara Biotherapeutics: ClinicalTrials.gov Identifier: NCT03394365 Obsolete Identifiers: NCT03392142: Other Study ID Numbers: ATA129-EBV-302 : First Posted: January 9, 2024 Key Record Dates: Last Update Posted: June 24, 2024 Last Verified: ...
WebDec 1, 2024 · 1 December 2024. Atara Bio has announced that the EMA has fully validated the Marketing Authorisation Application (MAA) for tabelecleucel (tab-cel®), and is the first regulatory agency in the world to review an off-the-shelf allogeneic T-cell therapy. Tab-cel has been described as an investigational treatment for patients with Epstein-Barr ... WebJun 7, 2024 · Atara is applying this one platform to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV + PTLD) and ...
WebOct 4, 2024 · Atara will retain full rights to tab-cel ® in other major markets, including North America, Asia Pacific, and Latin America. Under the terms of the agreement, Atara will … WebMar 1, 2024 · Now ATA3271, ATA3219 tab-cel and ATA188 all utilize Atara’s allogeneic EBV T-cell platform, the safety and tolerability for which has been validated by clinical studies and the experiences in ...
WebDec 14, 2024 · Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced efficacy and safety results from its Phase 3 multicenter ALLELE study investigating tabelecleucel (tab …
WebDec 14, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel in Phase 3 development for Epstein-Barr virus-driven post ... arcadia beddingWebMar 15, 2024 · Atara Bio presents Phase 2 tab-cel data in Epstein-Barr virus-driven PTLD Mar. 15, 2024 12:16 AM ET Atara Biotherapeutics, Inc. (ATRA) By: Mamta Mayani , SA News Editor 1 Comment arcadia beach resort pattaya pantipWebAug 17, 2024 · Conclusion. The final conclusion is that Atara Biotherapeutics is a great speculative biotech play to look into. That's because it holds the ability to receive two regulatory approvals for tab-cel ... arcadia beekman soapWebSep 29, 2024 · In October 2024, Atara entered into an exclusive commercialization agreement with Pierre Fabre for tab-cel in Europe, the Middle East, Africa, and select emerging markets for EBV-positive cancers ... arcadia bedeutungWebAtara Pipeline; Tab-cel ... Atara Bio is an equal opportunity employer and makes employment decisions on the basis of merit and other lawful factors. In accordance with applicable law, the Company prohibits discrimination based on race, color, religion, creed, sex, gender (including pregnancy, childbirth or medical condition related to ... arcadia beach ukraineWebSep 28, 2024 · Atara is leveraging its first-in-kind allogeneic off-the-shelf EBV T-cell platform to develop transformative therapies for patients including tab-cel ®, which … arcadia berlinWebDec 19, 2024 · Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for … arcadia ben zhang